News

You have been reaching out to us with your questions and concerns about the COVID-19 vaccines and we are grateful that you…

The Platelet Disorder Support Association recently recorded a patient education webinar on the new COVID-19 vaccines and immune thrombocytopenic purpura (ITP) As…

The focus of the HOPE-B trial is etranacogene dezaparvovec, uniQure’s investigational gene therapy candidate for individuals with severe and moderately severe hemophilia…

The new law lowers costs and opens up new options to get health insurance coverage. The American Rescue Plan (ARP), signed into…

In the age of high deductibles and patient out-of-pocket expenditures, more and more people depend on copay assistance to afford their life-saving…

Phone2Action is a new software system that allows GLHF to connect with you regarding our state advocacy work. It gives us the…

Spark Therapeutics announced preliminary data from part one of their ongoing phase 1/2 open-label, non-randomized, dose-finding study of SPK-8016, the company’s investigational…

Source: Joint statement from the European Hemophilia Consortium, the World Federation of Hemophilia, and the National Hemophilia Foundation Fitusiran update following EAHAD…

This year, in celebration of World Hemophilia Day, Saturday, April 17, we’re challenging the bleeding disorders community to a friendly game of…

Scientists – including Dr. Fauci – are estimating that around 90% of the US population would need to be either recovered from…

CDC COVID Data Tracker: To date, there have been 27,879,604 cases reported in the US resulting in nearly 500,000 deaths of Americans!…

by: Dr. Leonard Valentino, Chief Executive Officer, National Hemophilia Foundation So, where are we with vaccines for COVID-19? Well, let’s first start…

Answers for the bleeding disorders community to frequently asked questions about the vaccine. Read more. Source: National Hemophilia Foundation, HemaWare.

Learn about the power of advocacy in the bleeding disorders community. Read more. Source: National Hemophilia Foundation, HemaWare.  

In this video, Kollet Koulianos from NHF’s Payer Relations team explains the significance of copay Accumulator Adjustment programs. Watch now. Source: National…

The guidelines were developed by panels of 32 individuals, including hematologists, people living with VWD, and scientists with expertise in guideline development…

The phase 3 trial currently includes 134 participants with hemophilia A, all of whom have received a single dose of the gene…

by: Laurence Woollard, Hemophilia Influencer © PEN (Parent Empowerment Newsletter), LA Kelley Communications, Inc. The unparalleled, seismic societal shifts over the past…

In this video, Dr. Phillip Jacobson of Rush University discusses vaccine administration and distribution, community risks, and vaccine delivery mechanisms. Watch Video.

COVID-19 Vaccines and Bleeding Disorders: FAQs These FAQs were created in anticipation of questions or concerns individuals with bleeding disorders may have…

Join us on February 13-14 for a special edition of Milwaukee’s Best Bloody…To Go! Keep an eye on your email and social…

The Consolidated Omnibus Appropriations Bill, 2021, signed into law by President Trump on December 27, 2020 included a number of provisions important…

What You May Feel After Getting the COVID-19 Vaccine It’s important that people understand that there may be some side effects after…

The National Hemophilia Foundation (NHF) will be hosting a series of weekly webinars every Wednesday at 1 p.m. CST (2 p.m. ET) beginning…